Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vlad Herlea is active.

Publication


Featured researches published by Vlad Herlea.


International Journal of Cancer | 2000

Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGFβRII, BAX, HMSH3, HMSH6, IGFIIR and BLM genes

George A. Calin; Roberta Gafà; Maria Grazia Tibiletti; Vlad Herlea; Gabriel Becheanu; Luigi Cavazzini; Giuseppe Barbanti-Brodano; Italo Nenci; Massimo Negrini; Giovanni Lanza

Colon carcinomas with microsatellite mutator phenotype exhibit specific genetic and clinico‐pathological features. This report describes the analysis of 63 “microsatellite instability‐high” (MSI‐H) tumors for the presence of mutations in microsatellites located in the coding regions (CDRs) of 6 genes: TGFβRII, BAX, hMSH3, hMSH6, IGFIIR, and BLM. The following frequencies of mutations were detected: TGFβRII (70%), BAX (54%), hMSH3 (36.5%), IGFIIR (22%), hMSH6 (17.5%), and BLM (16%). The overall picture revealed combinations of mutations suggestive of a progressive order of accumulation, with mutations of TGFβRII and BAX first, followed by frameshifts in hMSH3, hMSH6, IGFIIR, and BLM. Correlations with 12 clinico‐pathological parameters revealed that tumors with frameshifts in 1 or 2 CDRs were significantly better differentiated than tumors with frameshifts in more than 2 CDRs. We also found that mutations in the hMSH3 gene were significantly associated with decreased wall invasiveness and aneuploidy, and frameshifts in the BLM gene were significantly associated with the mucinous histotype. A trend toward an association between hMSH3 and IGFIIR with the medullary and conventional adenocarcinoma histotypes, respectively, was seen. Our results strengthen the concept that mutations in target genes have a role in the tumorigenic process of MSI‐H tumors, and indicate that frameshifts in microsatellites located in CDRs occur in a limited number of combinations that could determine distinct clinico‐pathological traits. Int. J. Cancer 89:230–235, 2000.


Carcinogenesis | 2010

Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer

Sylwia E. Wojcik; Simona Rossi; Masayoshi Shimizu; Milena S. Nicoloso; Amelia Cimmino; Hansjuerg Alder; Vlad Herlea; Laura Z. Rassenti; Kanti R. Rai; Thomas J. Kipps; Michael J. Keating; Carlo M. Croce; George A. Calin

Cancer is a genetic disease in which the interplay between alterations in protein-coding genes and non-coding RNAs (ncRNAs) plays a fundamental role. In recent years, the full coding component of the human genome was sequenced in various cancers, whereas such attempts related to ncRNAs are still fragmentary. We screened genomic DNAs for sequence variations in 148 microRNAs (miRNAs) and ultraconserved regions (UCRs) loci in patients with chronic lymphocytic leukemia (CLL) or colorectal cancer (CRC) by Sanger technique and further tried to elucidate the functional consequences of some of these variations. We found sequence variations in miRNAs in both sporadic and familial CLL cases, mutations of UCRs in CLLs and CRCs and, in certain instances, detected functional effects of these variations. Furthermore, by integrating our data with previously published data on miRNA sequence variations, we have created a catalog of DNA sequence variations in miRNAs/ultraconserved genes in human cancers. These findings argue that ncRNAs are targeted by both germ line and somatic mutations as well as by single-nucleotide polymorphisms with functional significance for human tumorigenesis. Sequence variations in ncRNA loci are frequent and some have functional and biological significance. Such information can be exploited to further investigate on a genome-wide scale the frequency of genetic variations in ncRNAs and their functional meaning, as well as for the development of new diagnostic and prognostic markers for leukemias and carcinomas.


BMC Genetics | 2001

Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype

George Calin; Guglielmina Nadia Ranzani; Dino Amadori; Vlad Herlea; Irina Matei; Giuseppe Barbanti-Brodano; Massimo Negrini

BackgroundGenomic instability has been reported at microsatellite tracts in few coding sequences. We have shown that the Bloom syndrome BLM gene may be a target of microsatelliteinstability (MSI) in a short poly-adenine repeat located in its coding region. To further characterize the involvement of BLM in tumorigenesis, we have investigated mutations in nine genes containing coding microsatellites in microsatellite mutator phenotype (MMP) positive and negative gastric carcinomas (GCs).MethodsWe analyzed 50 gastric carcinomas (GCs) for mutations in the BLM poly(A) tract aswell as in the coding microsatellites of the TGFβ1-RII, IGFIIR, hMSH3, hMSH6, BAX, WRN, RECQL and CBL genes.ResultsBLM mutations were found in 27% of MMP+ GCs (4/15 cases) but not in any of the MMP negative GCs (0/35 cases). The frequency of mutations in the other eight coding regions microsatellite was the following: TGFβ1-RII (60 %), BAX (27%), hMSH6 (20%),hMSH3 (13%), CBL (13%), IGFIIR (7%), RECQL (0%) and WRN (0%). Mutations in BLM appear to be more frequently associated with frameshifts in BAX and in hMSH6 and/or hMSH3. Tumors with BLM alterations present a higher frequency of unstable mono- and trinucleotide repeats located in coding regions as compared with mutator phenotype tumors without BLM frameshifts.ConclusionsBLM frameshifts are frequent alterations in GCs specifically associated with MMP+tumors. We suggest that BLM loss of function by MSI may increase the genetic instability of a pre-existent unstable genotype in gastric tumors.


Chirurg | 2017

Curative-intent Surgery for Perihilar Cholangiocarcinoma with and without Portal Vein Resection - A Comparative Analysis of Early and Late Outcomes

Traian Dumitrascu; Cezar Stroescu; Vladislav Brasoveanu; Vlad Herlea; Mihnea Ionescu; Irinel Popescu

Introduction: The safety of portal vein resection (PVR) during surgery for perihilar cholangiocarcinoma (PHC) has been demonstrated in Asia, America, and Western Europe. However, no data about this topic are reported from Eastern Europe. The aim of the present study is to comparatively assess the early and long-term outcomes after resection for PHC with and without PVR. PATIENTS AND METHODS The data of 21 patients with PVR were compared with those of 102 patients with a curative-intent surgery for PHC without PVR. The appropriate statistical tests were used to compare different variables between the groups. Results: A PVR was performed in 17% of the patients. In the PVR group, significantly more right trisectionectomies (p=0.031) and caudate lobectomies (0.049) were performed and, as expected, both the operative time (p=0.015) and blood loss (p=0.002) were significantly higher. No differences between the groups were observed regarding the severe postoperative morbidity and mortality rates, and completion of adjuvant therapy. However, in the PVR group the postoperative clinicallyrelevant liver failure rate was significantly higher (p=0.001). No differences between the groups were observed for the median overall survival times (34 vs. 26 months, p = 0.566). A histological proof of the venous tumor invasion was observed in 52% of the patients with a PVR and was associated with significantly worse survival (p=0.027). CONCLUSION A PVR can be safely performed during resection for PHC, without significant added severe morbidity or mortality rates. However, clinically-relevant liver failure rates are significantly higher when a PVR is performed. Furthermore, increased operative times and blood loss should be expected when a PVR is performed. Histological tumor invasion of the portal vein is associated with significantly worse survival.


Chirurg | 2017

Resection of Concomitant Hepatic and Extrahepatic Metastases from Colorectal Cancer - A Worthwhile Operation?

Andrei Diaconescu; Sorin Alexandrescu; Zenaida Ionel; Cristian Zlate; Razvan Grigorie; Vladislav Brasoveanu; Doina Hrehoret; Silviu Ciurea; Florin Botea; Dana Tomescu; Gabriela Droc; Adina Croitoru; Vlad Herlea; Mirela Boros; Mugur Grasu; Radu Dumitru; Mihai Toma; Mihnea Ionescu; Catalin Vasilescu; Irinel Popescu

Background: The benefit of hepatic resection in case of concomitant colorectal hepatic and extrahepatic metastases (CHEHMs) is still debatable. The purpose of this study is to assess the results of resection of hepatic and extrahepatic metastases in patients with CHEHMs in a high-volume center for both hepatobiliary and colorectal surgery and to identify prognostic factors that correlate with longer survival in these patients. METHOD It was performed a retrospective analysis of 678 consecutive patients with liver resection for colorectal cancer metastases operated in a single Centre between April 1996 and March 2016. Among these, 73 patients presented CHEHMs. Univariate analysis was performed to identify the risk factors for overall survival (OS) in these patients. Results: There were 20 CHMs located at the lymphatic node level, 20 at the peritoneal level, 12 at the ovary and lung level, 12 presenting as local relapses and 9 other sites. 53 curative resections (R0) were performed. The difference in overall survival between the CHEHMs group and the CHMs group is statistically significant for the entire groups (p 0.0001), as well as in patients who underwent R0 resection (p 0.0001). In CHEHMs group, the OS was statistically significant higher in patients who underwent R0 resection vs. those with R1/R2 resection (p=0.004). Three variables were identified as prognostic factors for poor OS following univariate analysis: 4 or more hepatic metastases, major hepatectomy and the performance of operation during first period of the study (1996 - 2004). There was a tendency toward better OS in patients with ovarian or pulmonary location of extrahepatic disease, although the difference was not statistically significant. CONCLUSION In patients with concomitant hepatic and extrahepatic metastases, complete resection of metastatic burden significantly prolong survival. The patients with up to 4 liver metastases, resectable by minor hepatectomy benefit the most from this aggressive onco-surgical management.


Southeastern Geographer | 2018

Perihilar Cholangiocarcinoma on Biliary Anatomical Variant. Case Report

Florin Botea; Diana Nicolaescu; Alexandru Barcu; Nausica Picu; Radu Dumitru; Ruxandra Fota; Vlad Herlea; Irinel Popescu

Background. Perihilar cholangiocarcinoma (PCC), defined as tumors involving or in close vicinity to the main bile duct confluence, is the most frequent type of cholangiocarcinoma (CC). Nevertheless, PCC occurring on biliary anatomical variant is a rare condition, difficult to diagnose and to establish the proper surgical approach. Case presentation. A 59-year old male, with normal liver function, is incidentally diagnosed with PCC of the left hepatic duct (LHD), associated with a biliary anatomical variant consisting in right posterior hepatic duct (RPHD) entering the LHD. The patient underwent left hemihepatectomy with en-bloc resection of segment 1 and hilar lymph node dissection, and cholangiojejunostomy for the RPHD stump. Results. The intraoperative and postoperative outcome were remarkably uneventful. Negative resection margins of the operative specimen were observed at pathological examination. No local recurrence occurred during a 2-yr follow-up. Conclusion. Careful preoperative assessment and identification of anatomical variants are often the key to a successful surgical treatment in PCC.


Chirurg | 2017

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Răzvan Grigorie; Sorin Alexandrescu; Gabriela Smira; Mihnea Ionescu; Doina Hrehoreţ; Vladislav Brasoveanu; Simona Dima; Silviu Ciurea; Patricia Boeţi; Ionut Dudus; Nausica Picu; Radu Zamfir; Leonard David; Florin Botea; L. Gheorghe; Dana Tomescu; Ioana Lupescu; Mirela Boros; Mugur Grasu; Radu Dumitru; Mihai Toma; Adina Croitoru; Vlad Herlea; Cătălin Pechianu; Anca Năstase; Irinel Popescu

Background: The objective of this study is to assess the outcome of the patients treated for hepatocellular carcinoma (HCC) in a General Surgery and Liver Transplantation Center. Methods: This retrospective study includes 844 patients diagnosed with HCC and surgically treated with curative intent methods. Curative intent treatment is mainly based on surgery, consisting of liver resection (LR), liver transplantation (LT). Tumor ablation could become the choice of treatment in HCC cases not manageable for surgery (LT or LR). 518 patients underwent LR, 162 patients benefited from LT and in 164 patients radiofrequency ablation (RFA) was performed. 615 patients (73%) presented liver cirrhosis. Results: Mordidity rates of patient treated for HCC was 30% and mortality was 4,3% for the entire study population. Five year overall survival rate was 39 % with statistically significant differences between transplanted, resected, or ablated patients (p 0.05) with better results in case of LT followed by LR and RFA. Conclusions: In HCC patients without liver cirrhosis, liver resection is the treatment of choice. For early HCC occurred on cirrhosis, LT offers the best outcome in terms of overall and disease free survival. RFA colud be a curative method for HCC patients not amenable for LT of LR.


Chirurg | 2017

The Romanian National Program for Liver Transplantation - 852 Procedures in 815 Patients over 17 Years (2000-2017): A Continuous Evolution to Success

Irinel Popescu; Mihnea Ionescu; Vladislav Brasoveanu; Doina Hrehoreţ; Narcis Copca; Lupaşcu C; Florin Botea; Bogdan Dorobanţu; Sorin Alexandrescu; Mihai Grigorie; Emil Matei; Radu Zamfir; Vasile Lungu; Dana Tomescu; Gabriela Droc; Daniela Ungureanu; Ruxandra Fota; Graţiela Manga; Mihai Popescu; Laura Popa; L. Gheorghe; Speranţa Iacob; Corina Pietrăreanu; Mariana Mihailă; Laurenţiu Mic; Sanda Constantinescu; Cristian Gheorghe; Bogdan Cotruta; Ioana Lupescu; Mugur Grasu

Background: Liver transplantation (LT) has become an established treatment for end-stage liver disease, with more than 20.000 procedures yearly worldwide. The aim of this study was to analyze the results of Romanian National Program of LT. Methods: Between April 2000 and April 2017, 817 pts received 852 LTs in Romania. Male/female ratio was 487/330, while adult/pediatric ratio was 753/64, with a mean age of 46 years (median 50 yrs; range 7 months - 68 yrs). Main LT indications were HBV cirrhosis (230 pts; 28.2%), HCC (173 pts; 21.2%), and HCV cirrhosis (137 pts; 16.8%). Waiting time and indications for LT, patient and donor demographics, graft features, surgical procedures, and short and long-term outcomes were analyzed. Results: DDLT was performed in 682 pts (83.9%): whole LT in 662 pts (81%), split LT in 16 pts (2.3%), reduced LT in 2 pts (0.2%), and domino LT in 1 pts (0.1%). LDLT was performed in 135 pts (16.5%): right hemiliver in 93 pts (11.4%), left lateral section in 28 pts (3.4%), left hemiliver in 8 pts (1%), left hemiliver with segment 1 in 4 pts (0.5%), and dual graft LDLT in 2 pts (0.2%). Overall major morbidity rate was 31.4% (268 pts), while perioperative mortality was 7.9% (65 pts). Retransplantation rate was 4.3% (35 pts): 27 whole LTs, 3 reduced LTs, 3 split LTs, and 2 LDLT. Long-term overall 1-, 3-, and 5-year estimated survival rates for patients were 87.9%, 81.5%, and 79.1%, respectively. One-, 3-, and 5-year overall mortality on waiting list also decreased significantly over time from 31.4%, 54.1% and 63.5%, to 4.4%, 13.9% and 23.6%, respectively. Conclusions: The Romanian National program for liver transplantation addresses all causes of acute and chronic liver failure or liver tumors in adults and children, using all surgical techniques, with good long-term outcome. The program constantly evolved over time, leading to decreased mortality rate on the waiting list.


Romanian Journal of Internal Medicine | 2016

An Unusual Presentation of Plasma Cells – Castleman Disease: A Case Report

Mariana Mihăilă; Vlad Herlea; Camelia Dobrea; Ioana Lupescu; Gina Rusu Munteanu; Grethi Chiriac; Laurenţiu Micu; R. Serescu; Ionel Copaci

Abstract We present the case of a 76 year old female patient admitted in the Department of Cardiology for physical asthenia, profuse sweating and dyspnea with orthopnea for about one month. Clinical and paraclinical assessments performed at admission confirmed the diagnosis of cardiac tamponade. Surgical intervention was performed and 400 mL of clear effusion were drained. Post-operative evolution was marked by recurrence of symptoms, requiring after 3 weeks a new drainage of 600 mL of clear effusion, and biopsy of the pericardium was performed. Pathological exam described serous pericarditis with chronic inflammatory infiltrate, xanthogranulomatous reaction intricated in the pericardium and mesothelial hyperplasia. The patient was subsequently transferred to the Department of Internal Medicine for further investigations. Physical examination showed a patient with altered general status, pallor, vesicular murmur absent in both bases, presenting cutaneous hyperpigmentation at the level of the right hemi-abdomen and hip with posterior extension, and a peripheral indurated erythematous plaque. The patient presented nodular masses of 3 cm in the right latero-cervical and bilateral axillary regions, non-adherent to the superficial structures, as well as adenopathic blocks in both inguinal regions. CT scan of the thorax and abdomen showed moderate bilateral pleuresia, minimal pericardial effusion (15 mm) and multiple adenopathies on both sides of the diaphragm. Skin biopsy was performed, as well as bone marrow aspirate and excision of a right axillary lymph node. Pathological exams and immunohistochemistry tests confirmed the diagnosis of Plasma Cells Castleman disease.


Cancer Cell | 2007

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas

George A. Calin; Chang Gong Liu; Manuela Ferracin; Terry Hyslop; Riccardo Spizzo; Cinzia Sevignani; Muller Fabbri; Amelia Cimmino; Eun Joo Lee; Sylwia E. Wojcik; Masayoshi Shimizu; Esmerina Tili; Simona Rossi; Cristian Taccioli; Flavia Pichiorri; Xiuping Liu; Simona Zupo; Vlad Herlea; Laura Gramantieri; Giovanni Lanza; Hansjuerg Alder; Laura Z. Rassenti; Stefano Volinia; Thomas D. Schmittgen; Thomas J. Kipps; Massimo Negrini; Carlo M. Croce

Collaboration


Dive into the Vlad Herlea's collaboration.

Top Co-Authors

Avatar

Irinel Popescu

Titu Maiorescu University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mihnea Ionescu

Carol Davila University of Medicine and Pharmacy

View shared research outputs
Top Co-Authors

Avatar

Dana Tomescu

Carol Davila University of Medicine and Pharmacy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cristian Gheorghe

Carol Davila University of Medicine and Pharmacy

View shared research outputs
Top Co-Authors

Avatar

L. Gheorghe

Carol Davila University of Medicine and Pharmacy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

George A. Calin

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge